CA-HEPTAGON
22.2.2016 08:02:35 CET | Business Wire | Press release
Heptagon (www.hptg.com ), an industry leader in 3D imaging, sensing and illumination solutions for the Internet of Things (IoT) and Smart Devices, today announced it has shipped over 2 billion units to customers. The company, which is headquartered in Singapore, recently opened a new factory with expanded capacity to ship 1 billion units per year. Heptagon serves some of the largest makers of mobile and IoT products in the world. Its success is attributed to relentless dedication to innovation, consistently delivering top-quality, high-performance products to market quickly, and leading edge wafer level manufacturing capabilities that meet the needs of the fast-paced and rapidly-evolving IoT and smart device industries.
"We are delighted to announce this latest milestone in our rapid growth and see this as ongoing acceptance by the market of our innovative, world-class products," says Christian Tang-Jespersen, CEO and President of Heptagon. "We look forward to continuing our strong growth and reaching our next billion units shipped milestone.”
"We are well positioned to pursue new market opportunities with the expansion of our fab in Woodlands, Singapore and the opening of our new factory in Ang Mo Kio, Singapore," says S.C. Leong, Heptagon’s Chief Operating Officer. “We remain committed to uncompromising quality and our proven ability to move quickly from white board to shipping 100s of millions of units."
In addition to opening the new factory in Singapore, Heptagon has expanded its sales, marketing and engineering presence in Silicon Valley as a result of strong customer interest in the company’s product and miniaturization, integration, optical and electrical design expertise. Heptagon’s newly created Silicon Valley Labs and Executive Briefing Center showcase the latest interface and sensing technologies while providing convenient access for the innovators and decision makers in Silicon Valley.
With in-depth and unique knowledge and expertise in all major 3D imaging and sensing technologies including stereo vision, structured light and Time-of-Flight (ToF), Heptagon is ready to address a fast-growing market segment of 3D. The company’s products continue to push the boundaries of what is possible in 3D today. As a pioneer of ToF imaging, it recently introduced the industry’s first multipoint 3D ranging sensor for mobile application. Further, its proprietary technologies like adaptive stereo enables indoor and outdoor imaging in a single solution and create a unique platform for 3D capturing where the adaptive illumination technology powers interference free multi-user applications as needed in collaborative augmented reality, automotive cockpits and digital signage.
The need to integrate heterogeneous technologies in miniaturized packages is rapidly becoming the enabler of next generation products in mobile, wearables and IoT. Over 20 years of innovation in technology, manufacturing and operations, as well as a rigorous supply chain management form the foundation for Heptagon’s differentiation and uniquely positions the company to innovate and rapidly bring world-class products to market.
About Heptagon
Heptagon (www.hptg.com ) provides complete 3D/imaging, illumination and optical sensing solutions for smart devices and the internet of things. With over 2 billion units shipped and 20 years of industry firsts in miniaturizing and integrating complex hardware and software systems, Heptagon has industry leading technology and services to enhance our customer’s competitiveness. Backed by world-class investors, Heptagon is a global company with research and development, sales and customer services teams located in Singapore, Zurich Switzerland, in Silicon Valley USA, and Shenzhen China.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160221005200/en/
Contact:
Heptagon
Scott Filler +1 408-329-8920
pr@hptg.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom